Marvel Biosciences Corp. (MBCOF), a biotechnology company developing therapeutics for treatments for neurological diseases and neurodevelopmental disorders, announced that the Australian patent application for its lead investigational therapeutic, MB-204, for autistic disorder was accepted and that the patent is expected to be granted shortly after August 28, 2026.
MB-204 is a fluorinated analogue of the approved adenosine A2a receptor antagonist Istradefylline, which is used for the treatment of Parkinson's Disease.
In pre-clinical toxicology testing studies, MB-204 has demonstrated superior pharmacokinetics and has shown promising preclinical efficacy in animal models of depression and autism-related disorder, including Rett Syndrome, noted the company. Supported by the preclinical efficacy and toxicology results, the company believes the new allowance may bolster MB-204, as it advances into Phase I clinical development.
"We are continuing to extend our composition-of-matter patent protection of MB-204 to all major markets", commented Marvel CEO Rod Matheson.
Marvel is also exploring MB-204's potential in rare disorders like Rett syndrome and Fragile X syndrome.
MBCOF has traded between $0.068 and $0.24 over the last year. The stock closed Friday's trade at $0.158.
MBCOF is currently trading down 2.21% at $0.15.For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.